Modeling Cardiomyopathies with iPSCs

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Medical Applications of iPS Cells

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Engineering

• Identifiers
  DOI 10.1007/978-981-13-3672-0_5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model

  2018cited by this paper
• Sodium channel current loss of function in induced pluripotent stem cell-derived cardiomyocytes from a Brugada syndrome patient

  2018cited by this paper
• Induced pluripotent stem cell technology and inherited arrhythmia syndromes.

  2018cited by this paper
• Modeling Treatment Response for Lamin A/C Related Dilated Cardiomyopathy in Human Induced Pluripotent Stem Cells

  2017cited by this paper
• Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach

  2017cited by this paper
• Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.

  2017cited by this paper
• Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes

  2017cited by this paper
• Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes.

  2017cited by this paper
• A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome

  2017cited by this paper
• Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes

  2017cited by this paper
• An abnormal TRPV4-related cytosolic Ca2+ rise in response to uniaxial stretch in induced pluripotent stem cells-derived cardiomyocytes from dilated cardiomyopathy patients.

  2017cited by this paper
• Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells

  2017cited by this paper
• Differential Sarcomere and Electrophysiological Maturation of Human iPSC-Derived Cardiac Myocytes in Monolayer vs. Aggregation-Based Differentiation Protocols

  2017cited by this paper
• Allele‐specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long‐QT syndrome with a CALM2 mutation

  2017cited by this paper
• Characterization of a Human Induced Pluripotent Stem Cell–Derived Cardiomyocyte Model for the Study of Variant Pathogenicity: Validation of a KCNJ2 Mutation

  2017cited by this paper
• Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair

  2017cited by this paper
• A BAG3 chaperone complex maintains cardiomyocyte function during proteotoxic stress.

  2017cited by this paper
• CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities.

  2017cited by this paper
• Modelling human calmodulinopathies with induced pluripotent stem cells: progress and challenges.

  2017cited by this paper
• Tbx20 controls the expression of the KCNH2 gene and of hERG channels

  2017cited by this paper
• Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes

  2017cited by this paper
• Inherited arrhythmia syndromes

  2017cited by this paper
• Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

  2017cited by this paper
• Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes

  2016cited by this paper
• Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.

  2016cited by this paper
• Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy

  2016cited by this paper
• Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia

  2016cited by this paper
• Distinctive Roles of Canonical and Noncanonical Wnt Signaling in Human Embryonic Cardiomyocyte Development

  2016cited by this paper
• Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient‐Derived iPSC Model

  2016cited by this paper
• Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.

  2016cited by this paper
• Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia

  2016cited by this paper
• A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy.

  2016cited by this paper
• Induced pluripotent stem cells: at the heart of cardiovascular precision medicine

  2016cited by this paper
• Novel calmodulin mutations associated with congenital long QT syndrome affect calcium current in human cardiomyocytes.

  2016cited by this paper
• Metabolomic Profiling of Pompe Disease‐Induced Pluripotent Stem Cell‐Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated with Cardiac and Skeletal Muscle Pathology

  2016cited by this paper
• A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation.

  2016cited by this paper
• Modeling structural and functional deficiencies of RBM20 familial dilated cardiomyopathy using human induced pluripotent stem cells.

  2016cited by this paper
• Genomic correction of familial cardiomyopathy in human engineered cardiac tissues.

  2016cited by this paper
• A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses

  2016cited by this paper
• Human engineered heart tissue as a model system for drug testing.

  2016cited by this paper
• Maturation status of sarcomere structure and function in human iPSC-derived cardiac myocytes.

  2016cited by this paper
• Induced Pluripotent Stem Cell – Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

  2016cited by this paper
• Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity

  2016cited by this paper
• Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction

  2016cited by this paper
• Induced pluripotent stem cell technology: a decade of progress

  2016cited by this paper
• A new hERG allosteric modulator rescues genetic and drug‐induced long‐QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells

  2016cited by this paper
• Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy

  2015cited by this paper
• Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes

  2015cited by this paper
• Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome

  2015cited by this paper
• Mutation-Specific Phenotypes in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or α-Tropomyosin Mutation for Hypertrophic Cardiomyopathy

  2015cited by this paper
• Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations

  2015cited by this paper
• Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient

  2015cited by this paper
• Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy

  2015cited by this paper
• Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function

  2015cited by this paper
• Cardiovascular pharmacogenomics: current status and future directions

  2015cited by this paper
• Generating patient-specific induced pluripotent stem cells-derived cardiomyocytes for the treatment of cardiac diseases

  2015cited by this paper
• Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy

  2015cited by this paper
• Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy.

  2015cited by this paper
• Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells

  2015cited by this paper
• Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells

  2014cited by this paper
• Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells

  2014cited by this paper
• Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease

  2014cited by this paper
• Pompe Disease Results in a Golgi-based Glycosylation Deficit in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes*

  2014cited by this paper
• Brugada Syndrome: A Heterogeneous Disease with a Common ECG Phenotype?

  2014cited by this paper
• Endothelin‐1 Induces Myofibrillar Disarray and Contractile Vector Variability in Hypertrophic Cardiomyopathy–Induced Pluripotent Stem Cell–Derived Cardiomyocytes

  2014cited by this paper
• Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: Disease mechanisms and pharmacological rescue

  2014cited by this paper
• Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium

  2014cited by this paper
• Small Molecule‐Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes

  2014cited by this paper
• Alteration in basal and depolarization induced transcriptional network in iPSC derived neurons from Timothy syndrome

  2014cited by this paper
• Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells.

  2014cited by this paper
• Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing.

  2014cited by this paper
• Chemically defined generation of human cardiomyocytes

  2014cited by this paper
• Modeling the mitochondrial cardiomyopathy of Barth syndrome with iPSC and heart-on-chip technologies

  2014cited by this paper
• Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.

  2013cited by this paper
• Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics

  2013cited by this paper
• ESICM 2013 - Abstracts of Oral Presentations and Poster Sessions

  2013cited by this paper
• Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy.

  2013cited by this paper
• Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.

  2013cited by this paper
• The Disease-Specific Phenotype in Cardiomyocytes Derived from Induced Pluripotent Stem Cells of Two Long QT Syndrome Type 3 Patients

  2013cited by this paper
• Modeling of Arrhythmogenic Right Ventricular Cardiomyopathy With Human Induced Pluripotent Stem Cells

  2013cited by this paper
• Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing.

  2013cited by this paper
• Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.

  2013cited by this paper
• CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia

  2013cited by this paper
• Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome

  2013cited by this paper
• Eag Domains Regulate LQT Mutant hERG Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

  2013cited by this paper
• Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome.

  2013cited by this paper
• Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.

  2012cited by this paper
• Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy

  2012cited by this paper
• Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells

  2012cited by this paper
• Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs

  2012cited by this paper
• Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Reveals Early and Delayed Afterdepolarizations

  2012cited by this paper
• Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia

  2012cited by this paper
• Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation

  2012cited by this paper
• SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells

  2011cited by this paper
• In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells

  2011cited by this paper
• Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture

  2011cited by this paper
• Using iPS cell-derived neurons to uncover cellular phenotypes associated with Timothy Syndrome

  2011cited by this paper
• Modelling the long QT syndrome with induced pluripotent stem cells

  2011cited by this paper
• Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome

  2011cited by this paper
• Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification.

  2011cited by this paper

• No citing papers are available for this paper.